What is Nanite?
Founded in 2020 and based in Boston, MA, Nanite is at the forefront of developing programmable polymer nanoparticles. Their core technology is engineered for non-viral gene delivery, a critical advancement in therapeutic applications. This focus positions Nanite within the rapidly growing fields of nanomedicine and gene therapy, offering a potentially safer and more efficient alternative to existing delivery systems. The company's work addresses a key challenge in biotechnology, aiming to unlock new treatment modalities for a range of diseases.
How much funding has Nanite raised?
Nanite has raised a total of $10M across 2 funding rounds:
Angel/Seed
$8M
Angel/Seed
$2M
Angel/Seed (2023): $8M with participation from Zetta Venture Partners, Arkitekt Ventures, and Cystic Fibrosis Foundation
Angel/Seed (2023): $2M led by Cystic Fibrosis Foundation
Key Investors in Nanite
Zetta Venture Partners
Zetta Venture Partners is a venture capital firm specializing in early-stage AI native startups, providing zero to one capital and hands-on support. They focus on impactful companies in AI and infrastructure sectors.
Arkitekt Ventures
Arkitekt Ventures is an early-stage venture fund focused on innovative healthcare delivery models and the application of frontier technology in medicine, investing in entrepreneurs transforming advanced science into health solutions.
Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is a non-profit organization dedicated to finding cures for cystic fibrosis and ensuring those living with the condition lead long and productive lives, providing crucial support for related research.
What's next for Nanite?
With the recent strategic investment, Nanite is poised for significant growth and expansion. The enterprise-level backing suggests a transition from early-stage development to scaling operations, potentially including further research, clinical trials, and manufacturing capabilities. This financing will likely enable Nanite to advance its programmable polymer nanoparticle technology towards commercialization, solidifying its position as a key player in the gene delivery market. Future developments may involve strategic partnerships and broader application of their technology across various therapeutic areas.
See full Nanite company page
